CN111410625A - 铁草胺琥珀酰亚胺活化酯的合成方法和应用 - Google Patents
铁草胺琥珀酰亚胺活化酯的合成方法和应用 Download PDFInfo
- Publication number
- CN111410625A CN111410625A CN201910006435.XA CN201910006435A CN111410625A CN 111410625 A CN111410625 A CN 111410625A CN 201910006435 A CN201910006435 A CN 201910006435A CN 111410625 A CN111410625 A CN 111410625A
- Authority
- CN
- China
- Prior art keywords
- activated ester
- ferrioxamine
- dfo
- succinimide
- succinimide activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 150000002148 esters Chemical class 0.000 title claims abstract description 31
- 229960002317 succinimide Drugs 0.000 title claims abstract description 30
- 238000001308 synthesis method Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229940079593 drug Drugs 0.000 claims abstract description 30
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960000958 deferoxamine Drugs 0.000 claims abstract description 22
- 230000002285 radioactive effect Effects 0.000 claims abstract description 17
- 239000002738 chelating agent Substances 0.000 claims abstract description 10
- 238000003384 imaging method Methods 0.000 claims abstract description 10
- 238000002372 labelling Methods 0.000 claims abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 8
- 239000002184 metal Substances 0.000 claims abstract description 7
- 229910052751 metal Inorganic materials 0.000 claims abstract description 7
- 238000002603 single-photon emission computed tomography Methods 0.000 claims abstract description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910001447 ferric ion Inorganic materials 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- -1 sulfonic group Chemical group 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 6
- 229960001484 edetic acid Drugs 0.000 claims description 6
- 238000005886 esterification reaction Methods 0.000 claims description 6
- BAERPNBPLZWCES-UHFFFAOYSA-N (2-hydroxy-1-phosphonoethyl)phosphonic acid Chemical compound OCC(P(O)(O)=O)P(O)(O)=O BAERPNBPLZWCES-UHFFFAOYSA-N 0.000 claims description 5
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 5
- 238000006473 carboxylation reaction Methods 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000002105 nanoparticle Substances 0.000 claims description 5
- 229940014800 succinic anhydride Drugs 0.000 claims description 5
- ODGZAAHTGUZDBN-UHFFFAOYSA-N 1-hydroxy-2,5-dioxopyrrolidine-3-carboxylic acid Chemical compound ON1C(=O)CC(C(O)=O)C1=O ODGZAAHTGUZDBN-UHFFFAOYSA-N 0.000 claims description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 238000006482 condensation reaction Methods 0.000 claims description 4
- 229960003330 pentetic acid Drugs 0.000 claims description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 4
- JPSKCQCQZUGWNM-UHFFFAOYSA-N 2,7-Oxepanedione Chemical compound O=C1CCCCC(=O)O1 JPSKCQCQZUGWNM-UHFFFAOYSA-N 0.000 claims description 3
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims description 2
- ZJHUBLNWMCWUOV-UHFFFAOYSA-N oxocane-2,8-dione Chemical compound O=C1CCCCCC(=O)O1 ZJHUBLNWMCWUOV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 6
- 238000012879 PET imaging Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- ADDQHLREJDZPMT-AWEZNQCLSA-N (S)-metamifop Chemical compound O=C([C@@H](OC=1C=CC(OC=2OC3=CC(Cl)=CC=C3N=2)=CC=1)C)N(C)C1=CC=CC=C1F ADDQHLREJDZPMT-AWEZNQCLSA-N 0.000 abstract description 3
- 239000012216 imaging agent Substances 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 150000001408 amides Chemical class 0.000 abstract description 2
- 238000009833 condensation Methods 0.000 abstract 1
- 230000005494 condensation Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- 150000001875 compounds Chemical class 0.000 description 19
- 229940120638 avastin Drugs 0.000 description 16
- 239000000047 product Substances 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 8
- 238000001819 mass spectrum Methods 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 238000012636 positron electron tomography Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000012831 peritoneal equilibrium test Methods 0.000 description 5
- 238000012877 positron emission topography Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012295 chemical reaction liquid Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000021523 carboxylation Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910005267 GaCl3 Inorganic materials 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于放射性药物标记技术领域,特别是涉及铁草胺琥珀酰亚胺活化酯的合成方法及其在放射性标记药物制备中的应用。本发明以去铁胺(DFO)为原料,合成铁草胺琥珀酰亚胺活化酯。该活化酯可以在温和条件下,与带有伯氨基的药物分子发生酰胺缩合反应生成铁草胺偶联物,再用金属螯合剂通过竞争反应除去三价铁离子,得到去铁胺偶联物。本发明还涉及所述放射性标记的去铁胺偶联物作为显像剂和治疗药物的用途,通过使用医用放射性核素(如89Zr、68Ga、67Ga、177Lu、111In、90Y)对去铁胺偶联物进行高效率标记,生成的标记药物可以用于活体PET显像、SPECT显像或放射性治疗。
Description
技术领域
本发明属于放射性药物标记技术领域,特别涉及铁草胺琥珀酰亚胺活化酯的合成方法及其在放射性标记药物制备中的应用。
背景技术
恶性肿瘤严重危害人民群众的身体健康。很多癌症发病早期无明显临床症状,具有高灵敏度和特异性的核医学PET和SPECT显像,可用于对早期肿瘤等疾病的监测和诊断。近年来发展的肿瘤免疫显像和治疗技术,是利用放射性核素标记的肿瘤特异性靶向抗体类药物进行非侵入式的PET、SPECT显像,或者进行放射性治疗,具有很高的临床潜力。一些重要的医用放射性核素是具有三价或更高价态的离子,如68Ga3+、67Ga3+、177Lu3+、90Y3+、89Zr4+、111In3+等。将这些高价放射性金属离子标记到药物分子一般利用双功能螯合剂来实现。DFO是金属离子螯合剂,在临床上用作急性铁中毒的解救药,同时因其金属络合物具有高度的稳定性,也可用于药物的高价放射性离子标记。目前,所用的DFO偶联剂有异硫氰酸衍生物(Df-Bz-NCS)和四氟苯酚酯衍生物(N-suc-DFO-TFP),分别见文献1(Eur.J.Nucl.Med.Mol.I 2010,37,250-259)和文献2(J Nucl Med.2003,44(8),1271-81)。
Df-Bz-NCS与抗体偶联路线如下:
N-suc-DFO-TFP与抗体偶联路线如下:
以上两种方法在螯合剂与药物分子偶联时需要在较高的pH条件下(9~10)进行,而在该pH条件下一些抗体等生物分子会出现沉淀或凝聚现象,失去生物活性。因此,这两种双功能偶联剂都具有一定的缺点。而且(以89Zr标记为例),Df-Bz-NCS的水溶性较差,难以用薄层色谱法(TLC)区分89Zr标记的药物分子与杂质89Zr-Df-Bz-NCS,从而不能简便的测定89Zr标记产物的放射化学纯度,而需用到复杂费时的HPLC法。
发明内容
本发明旨在采用活化酯法,以商业试剂去铁胺(DFO)为原料,利用羧酸酐与DFO分子中的氨基发生缩合反应生成带羧基的DFO衍生物,然后用三价铁离子对DFO分子上的羟肟基进行保护,生成铁草胺衍生物。利用该分子中的羧基进行酯化反应可得到铁草胺琥珀酰亚胺活化酯。所合成的铁草胺琥珀酰亚胺活化酯可以在温和的近生理pH条件下,与带有伯氨基的药物分子,如肿瘤靶向抗体、多肽以及纳米颗粒等,发生酰胺缩合反应得到铁草胺偶联物,再用金属螯合剂,如EDTA,竞争铁草胺偶联物中的Fe3+,得到去铁胺偶联物。进一步用医用放射性核素,如89Zr,68Ga,67Ga和111In等,对去铁胺偶联物进行高效率标记,生成的标记药物可以用于活体PET、SPECT显像剂或放射性治疗。
本发明的目的之一是提供一种新的铁草胺琥珀酰亚胺活化酯。
本发明的目的之二是提供铁草胺琥珀酰亚胺活化酯的合成方法。
本发明的目的之三是提供铁草胺琥珀酰亚胺活化酯在制备肿瘤诊断及治疗所用药物中的用途。
本发明的目的之四是采用铁草胺琥珀酰亚胺活化酯与带有伯氨基的药物分子偶联,制备去铁胺偶联物;从而进一步获得放射性标记的DFO-药物偶联物。
本发明的目的之五是提供放射性标记的DFO-药物偶联物用于活体PET、SPECT显像或放射性治疗的用途。
本发明的铁草胺琥珀酰亚胺活化酯具有如下式Ⅰ结构:
其中,n为2~5;R为氢原子、磺酸基、羧基、烷基、芳基。
本发明所述铁草胺琥珀酰亚胺活化酯是通过以下制备方法实现的,包括如下步骤:
(1)以去铁胺(DFO)为原料经羧酸化反应,制得羧酸化铁草胺;
(2)使用Fe3+对羧酸化铁草胺中的羟肟基进行保护;
(3)再经酯化反应,制得所述铁草胺琥珀酰亚胺活化酯。
合成路线如下:
其中,n为2~5;R为氢原子、磺酸基、羧基、烷基、芳基。
所述步骤(1)中采用的羧酸化试剂为丁二酸酐、戊二酸酐、己二酸酐、庚二酸酐或它们的任意混合物,优选羧酸化试剂为丁二酸酐。
所述步骤(2)中的Fe3+为FeCl3、Fe2(SO4)3、硫酸铁铵,优选Fe3+为FeCl3。
所述步骤(3)中酯化反应采用的试剂选自NHS、DSC、N-羟基琥珀酰亚胺磺酸钠盐、1-羟基-2,5-二氧代-3-吡咯烷羧酸、1-羟基-3-苄基-2,5-二氧代-3-吡咯烷、1-羟基-3-戊烷基-2,5- 二氧代-3-吡咯烷或它们的任意混合物,优选酯化试剂为NHS。
进一步地,所述铁草胺琥珀酰亚胺活化酯可不经纯化直接用于下步反应。
进一步地,所述铁草胺琥珀酰亚胺活化酯在制备肿瘤诊断及治疗所用药物中的用途。其中,肿瘤诊断即指PET或SPECT显像;放射性治疗是指利用放射性核素在衰变过程中,释放出的α射线或β射线等,近距离精准杀伤病变细胞和组织,达到治疗的目的。
本发明旨在采用所述铁草胺琥珀酰亚胺活化酯,制备放射性标记的DFO-药物偶联物的方法,包括如下步骤:
(1)所述铁草胺琥珀酰亚胺活化酯与带有伯氨基的药物分子发生缩合反应;
(2)再与金属螯合剂发生竞争反应,脱除Fe3+;
(3)最后经放射性核素标记,制得放射性标记的DFO-药物偶联物(式Ⅵ)。
合成路线如下:
其中,n为2~5;R为氢原子、磺酸基、羧基、烷基、芳基;X为药物分子;M为放射性核素。
所述步骤(1)中pH范围为6~10;优选地pH范围为7~9;更优选地pH范围为7~7.8。
所述步骤(1)所述带有伯氨基的药物分子,选自肿瘤靶向抗体、多肽以及纳米颗粒中的一种,优选药物分子为抗体,更优选地药物分子为单克隆抗体。
所述步骤(2)中金属螯合剂选自乙二胺四乙酸(EDTA)、氨基三乙酸(NTA)、羟基乙叉二膦酸(HEDP)、二乙撑三胺五乙酸(DTPA),优选金属螯合剂为EDTA。
所述步骤(3)中放射性核素选自89Zr、68Ga、67Ga、111In、177Lu、90Y中的一种;优选放射性核素为89Zr。
所述方法制备的核素标记的去铁胺偶联物在肿瘤诊断及治疗方面的用途。其中,肿瘤诊断即指PET或SPECT显像;放射性治疗是指利用放射性核素在衰变过程中,释放出的α射线或β射线等,近距离精准杀伤病变细胞和组织,达到治疗的目的。
本发明的有益效果:
本发明提供了一种全新的铁草胺琥珀酰亚胺活化酯,该铁草胺琥珀酰亚胺活化酯易于制备、成本较低;且与抗体等药物分子进行偶联时,pH条件温和,且可通过TLC方法快速方便地检测放化纯。采用该铁草胺琥珀酰亚胺活化酯法合成的放射性标记探针的血池循环时间长、体内稳定性好、肿瘤/非肿瘤(T/NT)比值高。诊断性核素标记的探针用于免疫PET显像时,特异性强,成像分辨率较高,显像效果好。治疗性核素标记的探针在肿瘤治疗方面也具有良好的应用前景。
附图说明:
图1为化合物Ⅱ-a的质谱(MS)图。
图2为化合物Ⅰ-a的质谱(MS)图。
图3为A549肺癌模型鼠给予[89Zr]-DFO-suc-Avastin尾静脉注射后44h、92h的PET影像图。
具体实施方式:
为了使本发明的内容更容易被清楚地理解,下文结合具体实施例对本发明的内容做进一步详细地说明,所述的实施例目的仅用于说明和描述本发明当前的最佳模式,但本发明的保护范围不以任何方式受此处所述实施例的限制。
实施例1
1)化合物Ⅱ-a的合成
取甲磺酸去铁胺DFO(500mg,0.761mmol)、丁二酸酐(760mg,7.59mmol)加入到吡啶(7.5mL)中,震荡溶解,25℃下搅拌过夜。
将反应液加到氢氧化钠(125mL,0.06mol/L)溶液中,25℃静置过夜,检测pH为7.5。向反应液内加入盐酸(18.5mL,6mol/L),检测pH为2,有白色沉淀生成。置于4℃冰箱 2h,离心后使用0.01mol/L HCl(150mL)洗涤,干燥,得白色粉末状产物化合物Ⅱ-a 417mg,产率83%。
MS谱图:M/Z[M-H]-=659.4。
2)化合物Ⅰ-a的合成
取FeCl3·6H2O(17.6mg,0.0697mmol)溶于乙腈(1.3mL)中,加入化合物Ⅱ-a(20mg,0.0303mmol),乙腈(5mL),震荡溶解,此时溶液呈棕红色。向反应液内依次加入EDC(126mg,0.657mmol)和NHS(90mg,0.782mmol),35℃下震荡过夜。
减压旋干后,用稀盐酸(3mL,0.01mol/L)溶解,经C-18柱纯化,用稀盐酸(60mL,0.01mol/L)洗柱,乙腈(1.5mL)淋洗回收,即刻减压抽滤旋干,得红色产物化合物Ⅰ-a 50mg,产率88%。
MS谱图:M/Z[M+Na]+=833.33。
3)化合物Ⅴ-a的合成
取100μL贝伐单抗(Avastin),用pH 7.0、50mmol/L HEPES缓冲溶液稀释至10mg/mL,加入化合物Ⅰ-a(30μL,5mmol/L的DMSO溶液),混匀后加入pH 7.6HEPES(500μL, 50mmol/L),室温下反应2h。加入pH 4.5EDTA(1mL,50mmol/L),于35℃下反应30min,得化合物Ⅴ-a粗品。
将离心纯化3次后的化合物Ⅴ-a用pH 7.0HEPES缓冲液稀释,于-20℃下保存待标记。
4)化合物Ⅵ-a的合成
取10μL放射性活度为300μCi的89Zr草酸溶液,加入pH 7.0HEPES缓冲液(100μL,0.25mol/L),用1mol/L碳酸钠溶液中和所述89Zr草酸溶液至pH 7.0。再向其中加入100μg 化合物Ⅴ-a,混合均匀,形成反应液,在25℃下反应40min,每隔10min轻摇一次,即得标记产物Ⅵ-a粗品。
将上述得到的标记产物化合物Ⅵ-a的混合液,加入用醋酸-醋酸钠缓冲溶液平衡过的 PD10凝胶柱,弃去前15滴,收集剩余单抗流出液。再向收集液中加入0.5%龙胆酸溶液,用0.22μm的无菌滤膜过滤,即得用于活体PET显像的放射性标记的单抗药物Ⅵ-a([89Zr]-DFO-suc-Avastin)。
5)[89Zr]-DFO-suc-Avastin的放射化学纯度测定
为测定上述方法得到的标记产物[89Zr]-DFO-suc-Avastin的放射化学纯度,采用以下方法:
(1)iTLC法测定放射化学纯度:参照中国药典2015年版第四部通则1401内放射化学纯度测定法测定上述标记产物的放射化学纯度。吸取2μL上述[89Zr]-DFO-suc-Avastin溶液,滴于iTLC玻璃纤维板(1cm×8cminstant silica gel strip),用含5%DMSO的柠檬酸-柠檬酸钠缓冲液,pH 4.5作为展开剂展开,用TLC扫描仪扫描,[89Zr]-DFO-suc-Avastin不能被展开(比移值为0-0.1),而89Zr-Df-N-suc-COOH和89Zr-草酸络合离子则被展开(比移值皆大约为0.8)。或者,吸取2μL上述[89Zr]-DFO-suc-Avastin溶液,滴于Whatman#1薄层色谱纸板上,用柠檬酸-柠檬酸钠缓冲液,pH 5作为展开剂展开,用TLC扫描仪扫描, [89Zr]-DFO-suc-Avastin不能被展开(比移值为0-0.1),而89Zr-Df-N-suc-COOH和89Zr-草酸络合离子则被展开(比移值皆大约为0.8)。测得所述[89Zr]-DFO-suc-Avastin的放射化学纯度为99%。
(2)HPLC法测定放射化学纯度:取30μL本实施例中得到的[89Zr]-DFO-suc-Avastin溶液,用300×7.8mm规格的凝胶色谱柱(Tosoh TSK GEL,G3000SWXL)进行HPLC分离,流动相为0.1M的PBS缓冲液-0.2M NaCl,流速为1mL/min,同时进行紫外和放射性检测,紫外的检测波长为260nm。测得所述[89Zr]-DFO-suc-Avastin的放射化学纯度为99%。
6)[89Zr]-DFO-suc-Avastin的体内外稳定性测定
将标记产物[89Zr]-DFO-suc-Avastin在室温下放置12h后,放射性化学纯度为99%;将其分别置于小鼠血清和生理盐水中,于37℃水浴箱中孵育12h后,放射性化学纯度分别为98%和98%,表明其具有良好的体内外稳定性。
7)[89Zr]-DFO-suc-Avastin PET显像实验
向BALB/c裸小鼠皮下种植A549非小细胞肺癌细胞,建立相应的肿瘤动物模型。对荷瘤小鼠静脉注射约100μL纯化后的[89Zr]-DFO-suc-Avastin(约100μCi 89Zr),随后在44h和92h等不同时间点进行PET扫描。
初步结果显示,标记产物在小鼠体内显像分辨率高,能特异性对肿瘤进行显像,成像效果良好,是比较优良的显像剂。
实施例2
将实施例1中制备化合物Ⅱ-a的丁二酸酐分别替换为戊二酸酐、己二酸酐,制备相应的铁草胺琥珀酰亚胺活化酯。
MS谱图:M/Z[M+Na]+分别为847.36、861.39。
实施例3
将实施例1中制备化合物Ⅰ-a的NHS分别替换为DSC、1-羟基-2,5-二氧代-3-吡咯烷羧酸、 N-羟基琥珀酰亚胺磺酸钠盐,制备相应的铁草胺琥珀酰亚胺活化酯。
MS谱图:M/Z[M+Na]+分别为833.37、877.43、913.36。
实施例4
取100μL单克隆抗体Herceptin,用溶于pH 9.0、50mmol/L HEPES缓冲溶液稀释至10 mg/mL,加入经N-羟基琥珀酰亚胺磺酸钠盐制备的铁草胺琥珀酰亚胺活化酯(30μL,5mmol/L 的DMSO溶液),混匀后加入pH 9.0HEPES(500μL,50mmol/L),室温下反应2h。加入pH4.5NTA(1mL,50mmol/L),35℃下反应30min,得铁草胺偶联物粗品。
将得到的粗品用超滤管纯化,得精制的铁草胺偶联物,-20℃下保存待标记。
取10μL放射性活度为300μCi的68GaCl3的NaOAc溶液,再向其中加入100μg上述铁草胺偶联物,混合均匀,在90℃下反应20min,每隔5min摇匀一次,即得68Ga标记产物粗品。
将上述得到的68Ga标记产物的混合液,加入用醋酸-醋酸钠缓冲溶液平衡过的PD10柱,弃去前15滴,收集剩余流出液。再将收集液用0.22μm的无菌滤膜过滤,即得用于活体PET显像的放射性药物化合物[68Ga]-DFO-suc-Herceptin。
本实施例的标记产物在小鼠体内能特异性对肿瘤进行显像,成像效果良好。
实施例5
取氨基化的纳米颗粒,加入经1-羟基-2,5-二氧代-3-吡咯烷羧酸制备的铁草胺琥珀酰亚胺活化酯的DMSO溶液,混匀后加入pH 6.0HEPES,室温下反应2h。加入pH 4.5HEDP,35℃下反应30min,得铁草胺偶联物粗品。
将上述铁草胺偶联物用1:10氨水调pH值至7.0,加入10μL放射性活度为300μCi的177LuCl3,混合均匀,50℃反应15min,每隔5min摇匀一次,即得177Lu标记产物粗品。
将上述得到的177Lu标记产物的混合液,加入用醋酸-醋酸钠缓冲溶液平衡过的PD10柱,弃去前15滴,收集剩余流出液。再将收集液用0.22μm的无菌滤膜过滤,即得用于活体PET 显像的放射性药物化合物[177Lu]-DFO-suc-纳米颗粒。
经治疗后,可见A549肺癌模型鼠体内的肿瘤体积和数量均有一定程度的减少,该标记产物有明显抑制肿瘤生长的作用。
Claims (9)
3.如权利要求1或2所述的一种铁草胺琥珀酰亚胺活化酯的合成方法,其特征在于,包括如下步骤:
(1)以去铁胺(DFO)为原料经羧酸化反应,制得带羧基的DFO衍生物;
(2)使用三价铁盐对带羧基的DFO衍生物中的羟肟基进行保护;
(3)再经酯化反应,制得所述铁草胺琥珀酰亚胺活化酯。
4.如权利要求3所述的一种铁草胺琥珀酰亚胺活化酯的合成方法,其特征在于,所述步骤(1)中使用的羧酸化反应采用的试剂选自丁二酸酐、戊二酸酐、己二酸酐、庚二酸酐;所述步骤(3)中酯化反应采用的试剂选自N-羟基琥珀酰亚胺(NHS)、N,N-琥珀酰亚胺基碳酸酯(DSC)、N-羟基琥珀酰亚胺磺酸钠盐、1-羟基-2,5-二氧代-3-吡咯烷羧酸、1-羟基-3-苄基-2,5-二氧代-3-吡咯烷、1-羟基-3-戊烷基-2,5-二氧代-3-吡咯烷。
5.一种使用如权利要求1所述的铁草胺琥珀酰亚胺活化酯制备放射性核素标记的去铁胺偶联物的方法,其特征在于,包括如下步骤:
(1)所述铁草胺琥珀酰亚胺活化酯与带有伯氨基的药物分子发生缩合反应;
(2)再与金属螯合剂发生竞争反应,脱除Fe3+;
(3)最后经放射性核素标记,制得放射性标记的DFO-药物偶联物。
6.如权利要求5所述的方法,其特征在于,所述步骤(1)中pH范围为6~10;所述带有伯氨基的药物分子,选自肿瘤靶向抗体、多肽以及纳米颗粒中的一种;所述步骤(2)中金属螯合剂选自乙二胺四乙酸(EDTA)、氨基三乙酸(NTA)、羟基乙叉二膦酸(HEDP)、二乙撑三胺五乙酸(DTPA);所述步骤(3)中放射性核素选自89Zr、68Ga、67Ga、111In、177Lu、90Y中的一种。
7.如权利要求1所述的铁草胺琥珀酰亚胺活化酯在制备肿瘤诊断及治疗所用药物中的用途。
8.如权利要求6所述方法制备的核素标记的DFO-药物偶联物在肿瘤诊断及治疗方面的用途。
9.如权利要求7或8所述的用途,其特征在于,所述肿瘤诊断是PET或SPECT显像诊断。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006435.XA CN111410625A (zh) | 2019-01-04 | 2019-01-04 | 铁草胺琥珀酰亚胺活化酯的合成方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910006435.XA CN111410625A (zh) | 2019-01-04 | 2019-01-04 | 铁草胺琥珀酰亚胺活化酯的合成方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111410625A true CN111410625A (zh) | 2020-07-14 |
Family
ID=71486799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910006435.XA Pending CN111410625A (zh) | 2019-01-04 | 2019-01-04 | 铁草胺琥珀酰亚胺活化酯的合成方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111410625A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725510A (zh) * | 2015-01-27 | 2015-06-24 | 米度(南京)生物技术有限公司 | 89Zr标记伊匹单抗的标记产物及其制备方法、质量控制方法 |
CN107281498A (zh) * | 2017-06-16 | 2017-10-24 | 四川大学华西医院 | 一种聚乙二醇修饰的铁离子螯合剂 |
-
2019
- 2019-01-04 CN CN201910006435.XA patent/CN111410625A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104725510A (zh) * | 2015-01-27 | 2015-06-24 | 米度(南京)生物技术有限公司 | 89Zr标记伊匹单抗的标记产物及其制备方法、质量控制方法 |
CN107281498A (zh) * | 2017-06-16 | 2017-10-24 | 四川大学华西医院 | 一种聚乙二醇修饰的铁离子螯合剂 |
Non-Patent Citations (5)
Title |
---|
BRIAN M.ZEGLIS等: "Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels Alder Click Chemistry", 《BIOCONJUGATE CHEM.》, vol. 22, 31 August 2011 (2011-08-31), pages 2048 - 2059, XP055069716, DOI: 10.1021/bc200288d * |
IRIS VEREL, MS等: "89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-Labeled Monoclonal Antibodies", 《THE JOURNAL OF NUCLEAR MEDICINE》, vol. 44, no. 8, 31 August 2003 (2003-08-31), pages 1273, XP002615666 * |
PETER M.IHNAT等: "Synthesis and Solution Properties of Deferoxamine Amides", 《JOURNAL OF PHARMACEUTICAL SCIENCES》, vol. 89, no. 12, 31 December 2000 (2000-12-31), pages 1525 - 1536, XP008134135, DOI: 10.1002/1520-6017(200012)89:12<1525::AID-JPS3>3.0.CO;2-T * |
V.RADCHENKO等: "90Nb-a potential PET nuclide:production and labeling of monoclonal antibodies", 《RADIOCHIM. ACTA》, vol. 100, 10 April 2012 (2012-04-10), pages 860 * |
曾戎: "《多糖基高分子-药物轭合物的设计、合成、表征和评价》", 31 May 2011, 华南理工大学出版社, pages: 73 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112194651B (zh) | 一种pet示踪剂的前体化合物及其应用 | |
AU596590B2 (en) | Method of forming a metal chelate protein conjugate | |
AU641421B2 (en) | Chelating agents for forming complexes with radioactive isotopes, metal complexes thereof and use thereof in diagnosis and therapy | |
CA2040204C (en) | Chelating compounds and their use | |
US9550001B2 (en) | Compositions, methods of synthesis and use of carbohydrate targeted agents | |
JP2857095B2 (ja) | ジホスホネート誘導高分子類 | |
JPH07504661A (ja) | 放射免疫イメージング及び放射免疫療法に関するビオチン及びデフェロキサミンのコンジュゲート | |
JP2014503546A (ja) | 放射性標識her2結合ペプチド | |
JP6661010B2 (ja) | ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物 | |
CN114773433B (zh) | 一种cd25靶向多肽、分子探针及应用 | |
CN110496233B (zh) | 一种spect显像剂及其标记前体及其制备方法、组合物和用途 | |
JPH09505061A (ja) | 固定化標識方法 | |
CN111410625A (zh) | 铁草胺琥珀酰亚胺活化酯的合成方法和应用 | |
JP6525968B2 (ja) | トランス−ジ−n−ピコリネートテトラアザシクロアルカンベースの鉛(ii)およびビスマス(iii)のキレート | |
JP2022529007A (ja) | 診断及び治療のための新規な放射性標識されたcxcr4を標的とする化合物 | |
JPH04120065A (ja) | 10−(2’−ヒドロキシ−3’−アルコキシ)−1,4,7−トリスカルボキシメチル−1,4,7,10−テトラアザシクロドデカン | |
WO2008124467A1 (en) | Bifunctional hydroxamic acid ligands and method of synthesis | |
CN114031652B (zh) | 一种含环己烷的葡萄糖衍生物及其应用 | |
IE904318A1 (en) | 10-(2'-hydroxy-3'-alkoxy-1,4,7-triscarboxymethyl-1,4,7,10,¹-tetraazacyclododecanes | |
WO1992011039A1 (en) | Derivatized tris-catechol chelating agents | |
CN112111269B (zh) | 一种荧光和镥-177双标记生物分子及其制备方法与应用 | |
RU2655965C2 (ru) | Способ получения комплекса технеция-99м с модифицированными специфичными мини-антителами для диагностики онкологических заболеваний с гиперэкспрессией her2/neu | |
US9079867B2 (en) | Polyazamacrocyclic compound, and a production method and a biomedical use therefor | |
US5274082A (en) | Paramagnetic complexes of chelating compounds | |
KR20170089245A (ko) | 방사성 금속 표지 벤조사이아졸 유도체 및 그 유도체를 포함하는 방사성 의약품 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200714 |
|
RJ01 | Rejection of invention patent application after publication |